Good news out. Finally they made a smart decision on Brightcell. News on the ph 2 by early 2nd qtr. 2014. Could be a positive even if they don't make the 50 patient goal. Lower enrollment doesn't necessarily mean it is not working. Lower expenses and more emphasis on Autogel generating income. Nov is the next big news from CMS on Autogel.
The good news is that management is finally listening. With an end date for the Phase II trial results in sight, at least some folks will be willing to take a shot. The power of the unblinded study will be low, with maybe only 20-25 treated patients (50% placebo) but if results show any promise, Aldagen will have some value.